Ligand Pharmaceuticals Inc.has earned a $1 million milestone payment from Merck following the FDA approval of NOXAFIL (posaconazole) injection (18 mg/mL), a new Captisol-enabled formulation for intravenous use. Under a commercial supply agreement, Ligand will sell Captisol to Merck for this product.   “We congratulate the project team at Merck on this important advancement in the treatment of invasive fungal infections,” said John Higgins, president and chief executive officer of Ligand Pharmace...